Место мононитратов в лечении ишемической болезни сердца
Место мононитратов в лечении ишемической болезни сердца
Небиеридзе Д.В. Место мононитратов в лечении ишемической болезни сердца. Consilium Medicum. 2008; 10 (12): 35–38.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Список литературы
1. Bredt DS. Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radic Res 1999; 31 (6): 577–96.
2. Szocs K. Endothelial dysfunction and reactive oxygen species production in ischemia/reperfusion and nitrate tolerance. Gen Physiol Biophys. 2004; 23 (3): 265–95.
3. Abrams J. Beneficial actions of nitrates in cardiovascular disease. Am J Cardiol. 1996; 77 (13): 31C–7C.
4. Abshagen U et al. Pharmacokinetics of intravenous and oral isosorbide-5-mononitrate. Eur J Clin Pharmacol 1981; 20: 269–75.
5. Abshagen U. Pharmacokinetics of isosorbide mononitrate. Am Cardiol 1992; 70: 61G–66G.
6. Steudel HC et al. Pharmacokinetics of isosorbide-5-mononitrate after oral and intravenous administration in patients with liver cirrhosis: first results. Z Kardiol 1983; 72 (suppl. 3): 24–8.
7. Horowitz JD. Amelioration of nitrate tolerance: matching strategies with mechanisms. J Am Coll Cardiol. 2003; 41 (11): 2001–3.
8. Белоусов Ю.Б. Клиническая фармакологитя моночинкве, моночинкве ретард (изосорбида-5-мононитрата).
9. Lai C et al. A new anti-ischemic drug for the treatment of stable effort angina pectoris: nicorandil. Comparison with placebo and isosorbide-5-mononi-trate. Cardiologia 1991; 36: 703–11.
10. Bayerle A et al. Long-acting, marked antiischemic effect maintained unat-tenuated during long-term interval treatment with once-daily isosorbide-5-mononitrate in sustained release form. Am J Cardiol 1990; 65: 1434–7.
11. Рекомендации по диагностике и лечению стабильной стенокардии. ВНОК, 2008 г.
2. Szocs K. Endothelial dysfunction and reactive oxygen species production in ischemia/reperfusion and nitrate tolerance. Gen Physiol Biophys. 2004; 23 (3): 265–95.
3. Abrams J. Beneficial actions of nitrates in cardiovascular disease. Am J Cardiol. 1996; 77 (13): 31C–7C.
4. Abshagen U et al. Pharmacokinetics of intravenous and oral isosorbide-5-mononitrate. Eur J Clin Pharmacol 1981; 20: 269–75.
5. Abshagen U. Pharmacokinetics of isosorbide mononitrate. Am Cardiol 1992; 70: 61G–66G.
6. Steudel HC et al. Pharmacokinetics of isosorbide-5-mononitrate after oral and intravenous administration in patients with liver cirrhosis: first results. Z Kardiol 1983; 72 (suppl. 3): 24–8.
7. Horowitz JD. Amelioration of nitrate tolerance: matching strategies with mechanisms. J Am Coll Cardiol. 2003; 41 (11): 2001–3.
8. Белоусов Ю.Б. Клиническая фармакологитя моночинкве, моночинкве ретард (изосорбида-5-мононитрата).
9. Lai C et al. A new anti-ischemic drug for the treatment of stable effort angina pectoris: nicorandil. Comparison with placebo and isosorbide-5-mononi-trate. Cardiologia 1991; 36: 703–11.
10. Bayerle A et al. Long-acting, marked antiischemic effect maintained unat-tenuated during long-term interval treatment with once-daily isosorbide-5-mononitrate in sustained release form. Am J Cardiol 1990; 65: 1434–7.
11. Рекомендации по диагностике и лечению стабильной стенокардии. ВНОК, 2008 г.
Авторы
Д.В.Небиеридзе
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.